Who is sponsoring NCT00783315?

NCT00783315 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT00783315?

Interventions in NCT00783315: Call-Center Directed (CCD) Weight Loss Program, In-Person Directed (IPD) Weight Loss Program, Self-Directed Weight Loss Program.

Is NCT00783315 still recruiting?

NCT00783315 is currently completed. Last updated 5 September 2018.

Last reviewed 2018-09-05 · How we verify

NCT00783315: POWER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)

Completed NA Last updated 5 September 2018

What this trial tests

NA trial testing Call-Center Directed (CCD) Weight Loss Program in Obesity in 415 participants. Completed in 28 February 2011.

Timeline

1 February 2008

Primary endpoint
28 February 2011

28 February 2011

Quick facts

Lead sponsor	Johns Hopkins University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	415
Start date	1 February 2008
Primary completion	28 February 2011
Estimated completion	28 February 2011
Sites	1 location across United States

Drugs / interventions tested

Call-Center Directed (CCD) Weight Loss Program
In-Person Directed (IPD) Weight Loss Program
Self-Directed Weight Loss Program

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Johns Hopkins University

Who can join

21 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Many people who are obese also have high blood pressure, high cholesterol, or diabetes-all conditions that can increase the risk of heart disease. This study will evaluate two programs that aim to encourage weight loss among obese people who are at risk for developing heart disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Comparative effectiveness of weight-loss interventions in clinical practice.
Appel LJ, Clark JM, Yeh HC, Wang NY, et al · · 2011 · cited 549× · PMID 22085317 · DOI 10.1056/nejmoa1108660
Satisfaction with primary care provider involvement is associated with greater weight loss: Results from the practice-based POWER trial.
Bennett WL, Wang NY, Gudzune KA, Dalcin AT, et al · · 2015 · cited 32× · PMID 26026649 · DOI 10.1016/j.pec.2015.05.006
Insights from the POWER practice-based weight loss trial: a focus group study on the PCP's role in weight management.
Bennett WL, Gudzune KA, Appel LJ, Clark JM. · · 2014 · cited 32× · PMID 24002616 · DOI 10.1007/s11606-013-2562-6
Independent but coordinated trials: insights from the practice-based Opportunities for Weight Reduction Trials Collaborative Research Group.
Yeh HC, Clark JM, Emmons KE, Moore RH, et al · · 2010 · cited 29× · PMID 20573639 · DOI 10.1177/1740774510374213
Long-term effects of weight-reducing diets in people with hypertension.
Semlitsch T, Krenn C, Jeitler K, Berghold A, et al · · 2021 · cited 27× · PMID 33555049 · DOI 10.1002/14651858.cd008274.pub4
Longitudinal accuracy of web-based self-reported weights: results from the Hopkins POWER Trial.
Jerome GJ, Dalcin A, Coughlin JW, Fitzpatrick S, et al · · 2014 · cited 18× · PMID 25042773 · DOI 10.2196/jmir.3332
The relationship between sleep quantity, sleep quality and weight loss in adults: A scoping review.
Knowlden AP, Ottati M, McCallum M, Allegrante JP. · · 2024 · cited 12× · PMID 38140746 · DOI 10.1111/cob.12634
Role of PCP referral and weight loss in the Hopkins POWER trial.
Tseng E, Wang NY, Clark JM, Appel LJ, et al · · 2015 · cited 2× · PMID 26844176 · DOI 10.1016/j.pmedr.2015.11.002

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00783315 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 5 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00783315.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing